Ching Sung Hsu
Président chez Formosa Lithium Iron Oxide Corp.
Profil
Ching Sung Hsu is currently the Chairman at Formosa Lithium Iron Oxide Corp.
Prior to this, he held the position of Vice Chairman at United BioPharma, Inc. and UBI Pharma Inc. He also served as a Director at Changs Ascending Enterprise Co., Ltd.
and Taiwan Leader Biotech Corp.
where he held the position of Director from 2009 to 2017.
Mr. Hsu completed his undergraduate degree from Feng Chia University.
Postes actifs de Ching Sung Hsu
| Sociétés | Poste | Début |
|---|---|---|
| Formosa Lithium Iron Oxide Corp. | Président | - |
Anciens postes connus de Ching Sung Hsu
| Sociétés | Poste | Fin |
|---|---|---|
| TAIWAN LEADER BIOTECH CORP. | Directeur/Membre du Conseil | 30/03/2017 |
| UBI PHARMA INC. | Directeur/Membre du Conseil | - |
| UNITED BIOPHARMA INC | Directeur/Membre du Conseil | - |
| CHANGS ASCENDING ENTERPRISE CO., LTD. | Directeur/Membre du Conseil | - |
Formation de Ching Sung Hsu
| Feng Chia University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CHANGS ASCENDING ENTERPRISE CO., LTD. | Producer Manufacturing |
| TAIWAN LEADER BIOTECH CORP. | Health Technology |
| UBI PHARMA INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Formosa Lithium Iron Oxide Corp. | |
United BioPharma, Inc.
 United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |